Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The contributions of the XPD and XRCC1 allelic variants to OS are tumor site- and/or stage-dependent.
|
23894404 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Two of the common single-nucleotide polymorphisms X-ray repair cross-complementing group 1 (XRCC1) and Xeroderma pigmentosum group D (XPD) genes in PCa, which is one of the most common neoplasias in men all over the world, have been studied.
|
20070155 |
2010 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
To understand the relationship between deficient NER and tumor susceptibility, we used a mouse model for TTD that mimics an XPD point mutation of a TTD patient in the mouse germline.
|
10416615 |
1999 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
χ<sup>2</sup> tests showed that XRCC1-194, XRCC1-280 and XPD-312 gene polymorphisms were significantly correlated with the number, location and diameter of the tumors (p<0.05).
|
28927037 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERCC1 Lys259Thr (rs735482), ERCC2 Lys751Gln (rs13181), ERCC5 His46His C>T (rs1047768), XRCC1 Arg399Gln (rs25487), TP53 Arg72Pro (rs1042522) and MDM2 309T>G (rs2279744) were analyzed on tumor DNA.
|
28351583 |
2017 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In a separate genomic analysis, we detected significantly more likely deleterious somatic ERCC2 missense mutations in primary MIBC tumors in both the discovery (10.9% [36/330] vs 1.8% [1/55], p=0.04) and the validation (15.7% [12/70] vs 0% [0/24], p=0.03) cohort.
|
30290956 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Three tumors (all lower grade) showed concurrent allelic loss of ERCC1 and ERCC2.
|
8583241 |
1995 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The objective of this study was to investigate the association of XRCC3 Thr241Met and XPD Lys751Gln gene polymorphisms with the risk of CCRCC and the association between these genotypes and CCRCC histopathological prognostic factors (pathologic stage, Fuhrman grade, tumor diameter).
|
26682510 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Although two SNPs in BRCA2 (rs144848, rs1801406) and two SNPs in ERCC2 (rs1799793, rs13181) showed stronger associations with high Gleason score or advanced-stage tumors when comparing homozygous men carrying the minor versus major allele, results were not statistically significantly different between clinically aggressive and non-aggressive tumors.
|
19902366 |
2010 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
GSTP1 and ERCC2 genotypes were identified on DNA samples extracted from paraffin blocks containing either normal tissue (nodes) or tumor tissue.
|
18085999 |
2007 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, ERCC2 K751Q polymorphism was associated with an increased risk for non-cardial neoplasm [odds ratio (OR) = 1.78; 95% confidence interval (CI) 1.02-3.12], being ERCC2 K751Q and D312N polymorphisms associated with the diffuse type.
|
18641418 |
2008 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Several researchers have investigated the relationship between ERCC2 rs13181 and rs1799793 polymorphisms and chemotherapy efficacy in terms of tumour response and prognosis in gastric patients.
|
30581498 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In Ashkenazi patients, ERCC2 and MTHFR genes' SNPs were associated with age at diagnosis (ERCC2: p=0.025, MTHFR: p=0.0005); a P53 polymorphism, APOE and Rb SNPs with a family history of cancer (P53 p=0.034;APOE p=0.04, Rb p= 0.022); DCC SNP with tumor location (p=0.014); and p15 SNP with tumor grade (p=0.032).
|
15523694 |
2005 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
The frequency of the XPD 312Asn allele was significantly higher in T ≥ 2 high grade than in T ≥ 2 low grade tumors (p = 0.036); the ERCC6 1097Val/Val genotype was strongly associated with muscle-invasive tumors.
|
26649138 |
2016 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Our results revealed that individuals with ERCC2 rs13181TG/GG genotypes had a decreased risk of death compared with those with TT genotype [log-rank P = 0.008; adjusted hazard ratio = 0.68, 95% confidence interval = 0.51-0.91] and this protective effect was more pronounced among the subgroups of patients with tumour size ≤ 5 cm (0.59, 0.39-0.89), non-cardia gastric tumour (0.69, 0.48-0.98), no lymph node metastasis (0.55, 0.32-0.96), no distant metastasis (0.70, 0.52-0.95) and chemotherapy (0.39, 0.21-0.72).
|
23680703 |
2013 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
In conclusion, our results indicate that the <i>ERCC1</i> rs3212986 and the <i>ERCC2/XPD</i> rs1799793 could be used as surrogate markers for a better stratification of EC patients with advanced resectable tumor.
|
30847299 |
2019 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERCC2 G-C haplotype was correlated with PR negative and larger tumor (T4).
|
29544444 |
2018 |
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
ERCC1 (C8092A, C118T), XPD (Lys751Gln), XRCC1 (Arg399Gln) and XRCC3 (Thr241Met) gene polymorphisms were evaluated on tumour DNA by TaqMan allelic discrimination assay.
|
23549037 |
2013 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Allele XRCC2-188His [odds ratio (OR)=5.24, 95% confidence interval (CI)=4.36-6.29; p<0.0001], hOGG1-326Cys (OR=1.60, 95% CI=1.36-1.88; p<0.0001) and ERCC2-751Gln (OR=1.67, 95% CI=1.42-1.96; p<0.0001) strongly correlated with neoplastic disease.
|
30194171 |
2018 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this study was to investigate whether single nucleotide polymorphisms (SNPs) in polymorphisms of DNA repair gene ERCC1 (excision repair cross-complementation group 1) and XPD (ERCC2, excision repair cross-complementation group 2) were associated with the tumor response in advanced non-small-cell lung cancer (NSCLC) patients received platinum-based chemotherapy in Chinese population.
|
20351547 |
2010 |
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The role of individual polymorphisms has been evaluated for several genes including the CYP and glutathione s-transferase superfamilies, and the NAT genes; DNA repair genes such as XPD (nucleotide excision pathway), XRCC1 (base excision pathway), and MGMT; and tumor suppressor or cell cycle genes such as p53.
|
16052427 |
2005 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Further more, tumor samples with low ERCC1 mRNA expression levels showed enhanced CDDP cytotoxicity (P = 0.0001) while ERCC2 expression was reversely correlated with BCNU cytotoxicity (P = 0.004).
|
17151930 |
2007 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The NIR-regulated UCNP@TTD-cRGD NPs that were developed could selectively light up the targeted cancer cells and significantly inhibit tumor growth during the NIR-regulated PDT treatment as compared with the cells under white light excitation.
|
30662565 |
2019 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Polymorphisms in ERCC1, XPD, and XRCC1 were examined for (a) association with the clinical outcome of 107 non-small cell lung cancer patients receiving front-line platinum-based chemotherapy, and (b) correlation with the ERCC1 mRNA levels of 176 chemo-naive primary tumors.
|
25647444 |
2015 |
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Our data further imply that dPWP1 acts synergistically with mTOR signaling to regulate the nucleolar localization of TFIIH, a known elongation factor of Pol I. Ribosome biogenesis is often deregulated in cancer, and we demonstrate that high PWP1 levels in human head and neck squamous cell carcinoma tumors are associated with poor prognosis.
|
29065309 |
2017 |